fda warns semaglutide Approves Oral for Weight Loss FDA approves new weight-loss drug

Mimics natural GLP-1 A long-acting analog of glucagon-like peptide-1 the satiety hormone your gut releases after a meal

As of early 2026, orforglipron has completed or reported results from multiple Phase 3 trials

It also plays a role in pigment regulation, Kobets explains, helping with uneven tone and post-acne hyperpigmentation

There was no significant difference in terms of risk for diabetes during the first six months after treatment initiation (HR 0.99

On the other hand, its high reactivity also contributes to the uncontrolled removal of electrons, which underlies pathological cell damage through the propagation of highly reactive oxygen-containing molecules

Weeks 3-4: This timeframe typically brings more noticeable improvement